Diabetes mellitus affects more than 37 million Americans, and nearly all individuals with the condition will develop some form of diabetic eye disease over their lifetime. The most well-known complication is diabetic retinopathy, a progressive condition that damages the blood vessels in the retina and remains the leading cause of blindness among working-age adults in the United States. However, diabetes also dramatically increases the risk for other ocular surface disorders, including persistent dry eye syndrome, corneal neuropathy, and meibomian gland dysfunction. These conditions are caused in part by the metabolic disruptions that accompany chronic hyperglycemia, including inflammation, oxidative stress, and microvascular damage that reduces tear film stability.

For individuals managing diabetes, the choice of over-the-counter eye care products — including artificial tears, lubricating drops, rewetting solutions, and contact lens care products — is not a trivial matter. Many of these products contain ingredients that can either support or compromise the delicate ocular surface environment. Among the most consequential but often overlooked components is sodium. The concentration and type of sodium compounds used in eye drops can influence tear film osmolarity, corneal hydration, and the comfort of the eye. This is where the U.S. Food and Drug Administration (FDA) plays a critical role by enforcing labeling regulations that help consumers, particularly those with diabetes, make informed decisions.

Understanding the FDA Regulatory Framework for OTC Eye Care Products

The FDA regulates over-the-counter ophthalmic drug products under the Federal Food, Drug, and Cosmetic Act as well as the monograph system established by the OTC Drug Review. Eye drops, lubricating solutions, and similar products intended for therapeutic or palliative use are classified as OTC drugs rather than cosmetics. This classification subjects them to rigorous requirements for safety, efficacy, and labeling. The FDA’s authority extends to all ingredients present in these formulations, including active pharmaceutical ingredients, preservatives, buffering agents, stabilizers, and electrolytes such as sodium compounds.

The specific labeling requirements for OTC eye care products are detailed in Title 21 of the Code of Federal Regulations (21 CFR Part 349). These regulations mandate that the product label must include a complete list of ingredients, the net quantity of contents, the name and address of the manufacturer or distributor, and any required warning statements. For products that contain sodium compounds, the label must identify each sodium-containing ingredient by its established name (e.g., sodium chloride, sodium phosphate, sodium borate, or sodium hyaluronate). The regulations also require that the concentration of these ingredients be stated in terms of percentage weight by volume or in milligrams per milliliter where applicable.

Importantly, the FDA does not currently require a separate “Sodium” section on the Drug Facts panel for ophthalmic products in the way that the Nutrition Facts panel mandates for food products. However, because sodium compounds may serve as active ingredients, preservatives, or buffering agents, their presence and concentration must still be disclosed. This regulatory structure creates both opportunities and challenges for consumers with diabetes who need to monitor their sodium intake from multiple sources.

How the FDA Monograph System Applies to Eye Drops

The OTC Drug Review established monographs for categories of nonprescription drugs that are generally recognized as safe and effective (GRASE). Ophthalmic demulcents, astringents, and emollients are covered under the ophthalmic drug products monograph. Products that fall within this monograph can be marketed without a New Drug Application (NDA) as long as they comply with the monograph’s specifications for active ingredients, concentrations, labeling, and testing. The monograph explicitly lists permissible active ingredients for lubricating eye drops, including polyethylene glycol 400, propylene glycol, glycerin, and various cellulose derivatives. While sodium chloride is not listed as an active ingredient for demulcent claims, it commonly appears as an inactive ingredient used to adjust tonicity and maintain osmotic balance.

Manufacturers who choose to include sodium compounds outside the monograph’s specifications must either file an NDA or a Citizen Petition to amend the monograph. This regulatory pathway ensures that any sodium-related formulation decisions are backed by safety and efficacy data relevant to the intended use population, including individuals with diabetes.

Why Sodium Content Matters Specifically for Diabetic Eyes

The relationship between sodium levels in ocular products and diabetic eye health is complex but increasingly well understood. The tear film is a trilaminar structure composed of an outer lipid layer, an aqueous middle layer, and an inner mucin layer that bathes the corneal and conjunctival epithelium. The osmolarity of the tear film is tightly regulated by the lacrimal functional unit, and any disruption can lead to ocular surface inflammation, epithelial damage, and discomfort.

Individuals with diabetes frequently exhibit elevated tear film osmolarity due to reduced aqueous tear production, increased evaporation, and altered electrolyte composition of the tears themselves. Studies have shown that diabetic patients with dry eye disease have significantly higher tear film osmolarity compared to non-diabetic controls. When an eye drop containing a high concentration of sodium is instilled into a hyperosmolar tear film, it can create a transient osmotic gradient that draws water out of the corneal epithelium, leading to cellular shrinkage, desiccation, and increased release of inflammatory mediators. Over time, repeated exposure to hyperosmolar drops can exacerbate the cycle of inflammation and epithelial dysfunction that characterizes diabetic dry eye.

Conversely, eye drops formulated with a balanced electrolyte profile and appropriate tonicity can help restore the normal osmotic environment of the ocular surface. For diabetic patients, selecting a product with a sodium concentration that matches or slightly undercuts the natural tear osmolarity (typically around 300 to 310 mOsm/L) may reduce ocular surface stress and improve comfort. This makes the sodium content disclosed on product labels a critical data point for informed product selection.

The Role of Preservatives and Sodium Compounds

Many multi-dose eye drops contain preservatives to prevent microbial contamination after opening. One of the most common preservatives is benzalkonium chloride (BAK), a quaternary ammonium compound. While BAK itself does not contribute sodium, the buffering systems used in BAK-preserved formulations often include sodium phosphate, sodium borate, or sodium citrate. These buffering agents maintain the pH of the solution within the physiological range of 6.5 to 7.8, but they also add to the total solute load of the drop.

Preservative-free formulations, which are increasingly recommended for patients with moderate to severe dry eye or those who require frequent application, may use alternative packaging systems such as individual unit-dose vials. These products may still contain sodium compounds as tonicity adjusters, but they often have lower overall electrolyte concentrations and lack the epithelial toxicity associated with BAK. For diabetic patients with compromised corneal nerves and reduced epithelial healing capacity, preservative-free drops with carefully controlled sodium content are often the safest choice.

FDA Labeling Requirements in Detail

The Drug Facts labeling requirement for OTC eye care products follows a standardized format that consumers can learn to interpret quickly. The principal display panel must show the product name, the active ingredients and their purposes, and the net quantity. The Drug Facts panel, which appears on the side or back of the package, is divided into sections including Active Ingredients, Uses, Warnings, Directions, Other Information, and Inactive Ingredients.

Sodium compounds appear in the Inactive Ingredients section unless they serve as active ingredients, which is rare for lubricating drops. The listing must use the official USP nomenclature, so consumers will see terms like “sodium chloride,” “sodium phosphate (monobasic and dibasic),” “sodium borate,” “sodium hyaluronate,” “sodium carboxymethylcellulose,” or “sodium hydroxide,” which is used for pH adjustment. The concentration of each inactive ingredient is typically expressed as a percentage (w/v), although the FDA does not require specific quantification for all inactive ingredients in the Drug Facts panel. However, manufacturers who make “sodium-free” or “low-sodium” claims must have substantiation for those claims and may need to provide additional disclosure.

Decoding the Inactive Ingredients List for Diabetic Consumers

For diabetic patients, knowing where to look for sodium information is essential. The Inactive Ingredients section lists components in descending order of predominance. While inactive ingredients are not required to be listed with their exact quantitative values on the Drug Facts panel, many manufacturers voluntarily provide concentration data on the package or in the product’s prescribing information. The “Other Information” section may contain additional details about storage conditions and occasionally about electrolyte content.

Patients should understand that not all sodium-containing compounds are created equal. Sodium chloride is the primary tonicity agent in most conventional eye drops and is generally well tolerated at physiological concentrations (approximately 0.9% w/v). Sodium phosphate buffers are common in preserved drops and can contribute to total sodium load. Sodium hyaluronate, found in many preservative-free artificial tears, serves as a lubricant and moisture-retaining agent and typically contributes less osmotic stress than sodium chloride. Learning to recognize these different compounds enables more precise product selection.

Practical Implications for Manufacturers

Compliance with FDA sodium labeling regulations imposes both formulation and packaging requirements on manufacturers. Companies that produce eye care products for the diabetic population must consider not only the concentration of sodium compounds but also the overall tonicity and pH of the final product. Reformulation efforts may involve replacing sodium chloride with non-ionic tonicity agents such as glycerin, propylene glycol, or mannitol to reduce the sodium content while maintaining physiological osmolarity. Some manufacturers have successfully introduced “low-sodium” or “electrolyte-balanced” formulations specifically designed for patients with sensitive eyes or chronic dry eye associated with systemic conditions like diabetes.

Labeling compliance also extends to marketing claims. If a manufacturer promotes a product as “suitable for diabetics” or “low in sodium,” those claims must be truthful, not misleading, and supported by competent and reliable scientific evidence. The FDA may request substantiation for such claims during routine inspections or in response to consumer complaints. Additionally, products that deviate from the OTC monograph by using novel sodium compounds or concentrations outside the established range must undergo premarket review through the NDA or abbreviated new drug application (ANDA) process.

Quality Control and Batch-to-Batch Consistency

Maintaining consistent sodium content across production batches is critical for both regulatory compliance and patient safety. The FDA’s Current Good Manufacturing Practice (CGMP) regulations require manufacturers to test raw materials, in-process samples, and finished products for identity, strength, quality, and purity. For ophthalmic products, this includes verifying that the osmolality falls within the labeled specification range. Manufacturers must also conduct stability studies to ensure that sodium content does not change over the product’s shelf life due to interactions with the container closure system or other ingredients. Diabetic patients who rely on consistent product performance can take some reassurance from the regulatory framework that demands this level of quality assurance.

Practical Guidance for Diabetic Consumers Selecting Eye Drops

Given the complexity of product formulations and labeling, diabetic patients need a systematic approach to selecting eye care products. The following strategies integrate FDA regulatory knowledge with clinical best practices for ocular surface health.

Start with the Inactive Ingredients List

Before purchasing any OTC eye drop, flip the bottle or box to the Drug Facts panel and locate the Inactive Ingredients section. Identify every compound that contains the word “sodium.” Note the order in which they appear—ingredients are listed from highest to lowest concentration. A product that lists sodium chloride as the first inactive ingredient likely has the highest sodium load. Compare several brands to find options with fewer sodium compounds or with sodium compounds appearing later in the list.

Prioritize Preservative-Free Formulations

For diabetic patients who use artificial tears more than four times per day, preservative-free products are strongly recommended. The absence of benzalkonium chloride eliminates one source of ocular surface toxicity, and preservative-free products are often formulated with lower and better-balanced electrolyte concentrations. Although preservative-free products may cost more and come in single-use vials, the benefits for long-term ocular surface health can be significant. Many major brands offer preservative-free lines that are labeled clearly on the front of the package.

Look for Osmolality Information

Some manufacturers voluntarily include the osmolality of their product on the label or in the package insert. An osmolality between 270 and 310 mOsm/kg is generally considered isotonic and well tolerated. Products with osmolality above 320 mOsm/kg may be hypertonic and could exacerbate dryness in individuals with already elevated tear film osmolarity. If osmolality is not listed, contacting the manufacturer directly or visiting the product website can sometimes provide this information.

Consult a Healthcare Professional Before Making a Switch

While FDA labeling provides essential data, it cannot replace personalized medical advice. Diabetic patients should discuss their eye drop choices with an optometrist or ophthalmologist who understands their full medical history, including the stage of any diabetic retinopathy, the presence of corneal nerve damage, and concurrent medications that may affect the ocular surface. An eye care professional can recommend specific brands or formulations that align with the patient’s unique clinical profile and can also help interpret labeling information in the context of the patient’s overall diabetic management plan.

Future Directions in FDA Regulation of Ophthalmic Products

The regulatory landscape for OTC eye care products continues to evolve. In recent years, the FDA has taken steps to modernize the OTC monograph system through the CARES Act of 2020, which allows for more efficient updates to monograph requirements without full rulemaking. This flexibility could lead to more explicit labeling requirements for electrolytes, including sodium, in ophthalmic products. Patient advocacy groups and professional organizations such as the American Academy of Ophthalmology and the American Optometric Association have called for clearer disclosure of tonicity and electrolyte content to help patients with chronic conditions make better-informed choices.

Additionally, the FDA has shown increased interest in patient-focused drug development and the inclusion of patient experience data in regulatory decision-making. As more diabetic patients report the challenges of managing both systemic and ocular health, the agency may consider requiring a standardized “Electrolyte Information” section on the Drug Facts panel for ophthalmic products. Such a change would represent a significant victory for consumer transparency and would empower millions of Americans with diabetes to take greater control of their eye health.

The Growing Role of Digital Labeling and Mobile Access

Another trend worth watching is the FDA’s exploration of digital labeling options, including QR codes on product packaging that link to comprehensive ingredient information, clinical studies, and patient education materials. For diabetic consumers who want to compare sodium content across multiple products, a digital label could provide sortable data tables and personalized filtering tools. While still in the early stages, this approach aligns with broader federal efforts to improve health literacy and medication adherence through technology.

Conclusion

The FDA’s regulations on sodium labeling in eye care products serve a vital public health function by ensuring that consumers have access to accurate ingredient information. For the millions of Americans living with diabetes, this transparency is especially important because the sodium content of artificial tears and other ophthalmic products can directly affect ocular surface health, tear film stability, and overall comfort. Understanding how to read and interpret Drug Facts labels—including inactive ingredients, preservative types, and voluntary osmolality disclosures—empowers diabetic patients to select products that support rather than compromise their eye health.

Manufacturers who invest in low-sodium formulations, preservative-free delivery systems, and clear labeling will be well positioned to meet the needs of this growing patient population. Meanwhile, the FDA’s ongoing efforts to modernize the OTC monograph system and explore digital labeling innovations promise to make ingredient information even more accessible in the years ahead. By staying informed about both current regulations and emerging trends, diabetic patients and the eye care professionals who treat them can work together to protect vision and quality of life.

For further reading, consult the FDA’s official page on OTC ophthalmic drug products, the National Eye Institute’s overview of diabetic retinopathy, and the American Diabetes Association’s eye health resources for patients.